Skip to content
HowShorted

Axsome Therapeutics, Inc. short interest in 2021

In 2021, Axsome Therapeutics, Inc.'s disclosed short interest ran from 8.97% of shares outstanding on 15 Jan 2021 to 9.11% on 31 Dec 2021, a change of +0.14 percentage points. The year's high was 10.64% on 31 Aug 2021 and its low 7.23% on 15 Jul 2021, averaging 8.77% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 13.76 days on 12 Feb 2021. Full history: Axsome Therapeutics, Inc..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2018 · 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for Axsome Therapeutics, Inc. in 2021

2021 in figures

Start of year
8.97% (15 Jan 2021)
End of year
9.11% (31 Dec 2021)
Change
+0.14 pp
High
10.64% (31 Aug 2021)
Low
7.23% (15 Jul 2021)
Average
8.77%
Highest days to cover
13.76 (12 Feb 2021)
SEC filings marked
8

Every report in 2021

Axsome Therapeutics, Inc. short interest in 2021
SettlementShort interestDays to coverFilings since previous
15 Jan 20218.97%12.59
29 Jan 20219.03%11.42
12 Feb 20218.25%13.76
26 Feb 20218.61%12.54
15 Mar 20218.48%10.3710-K filed, results (8-K)
31 Mar 20217.77%9.15
15 Apr 20217.75%12.62
30 Apr 20218.31%5.93
14 May 20218.68%9.6110-Q filed, results (8-K)
28 May 20219.04%10.32
15 Jun 20218.85%10.09
30 Jun 20217.72%7.70
15 Jul 20217.23%7.79
30 Jul 20217.85%8.23
13 Aug 20219.02%1.3410-Q filed, results (8-K)
31 Aug 202110.64%1.77
15 Sep 20218.90%2.74
30 Sep 202110.02%3.63
15 Oct 20219.99%3.63
29 Oct 20218.85%5.21
15 Nov 20218.64%4.3810-Q filed, results (8-K)
30 Nov 20219.30%4.99
15 Dec 20219.57%7.25
31 Dec 20219.11%7.60

See also: Axsome Therapeutics, Inc.'s full history · most shorted US stocks of 2021 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.